4Moving Biotech
4Moving Biotech (4MB), a spin-off of 4P-Pharma, is a clinical-stage biotechnology company developing the first potential disease-modifying drug (DMOAD) for knee osteoarthritis. Their lead candidate, 4P004, is currently in a Phase 2a trial and aims to provide a sustainable therapeutic solution for the significant unmet medical need of osteoarthritis.
Funding Round: Grant
Funding Amount: €7.6M
Date: 08-Apr-2025
Investors: France 2030
Markets: Biotechnology, Pharmaceuticals, Research and Development, Osteoarthritis
HQ: Lille, Hauts-de-France, France
Founded: 2020
Website: https://www.4movingbiotech.com/
Leave a Comment
Comments
No comments yet.